[podcast]Brukinsa approval raises BeiGene’s hematology profile

BeiGene’s chief medical officer for hematology, Dr. Mehrdad Mobasher, tells Jack O’Brien about BTK inhibitor Brukinsa’s latest lymphoma approval from the FDA and offers messaging advice to medical marketers.